List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 110 studies with search of: aurora kinase
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma
Conditions: Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: Aurora kinase inhibitor AT9283
2 Terminated A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors
Condition: Solid Tumors
Intervention: Drug: CYC116
3 Terminated A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer
Condition: Cancer
Intervention: Drug: VX-680 (an Aurora Kinase Inhibitor)
4 Active, not recruiting CYC116 in Treating Patients With Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Aurora kinase/VEGFR2 inhibitor CYC116;   Other: high performance liquid chromatography;   Other: laboratory biomarker analysis;   Other: mass spectrometry;   Other: pharmacological study
5 Completed Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors
Condition: Solid Tumors
Intervention: Drug: PF-03814735
6 Terminated MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors
Conditions: Colorectal Cancer;   Advanced Solid Tumors
Intervention: Drug: MK0457, VX-680 (Aurora Kinase Inhibitor)
7 Recruiting AT9283 in Children and Adolescents With Relapsed or Refractory Solid Tumors
Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: Aurora kinase inhibitor AT9283;   Other: enzyme-linked immunosorbent assay;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: pharmacological study
8 Not yet recruiting A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors
Conditions: Advanced Malignancy;   Advanced Solid Tumors;   Cancer;   Solid Tumors;   Tumors
Interventions: Drug: Arm 1- Dose Escalation;   Drug: Arm 1- Dose Expansion
9 Completed Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors
Condition: Advanced Solid Tumors
Intervention: Drug: SNS-314
10 Recruiting Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
Conditions: Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndromes;   Myelofibrosis
Intervention: Drug: AT9283
11 Recruiting Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: bortezomib;   Drug: cladribine;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
12 Not yet recruiting TTP607 in Refractory Solid Malignancies
Conditions: Advanced Cancers;   Lymphoma
Intervention: Drug: TTP607
13 Recruiting MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
Conditions: Leukemia;   Neuroblastoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: Aurora A kinase inhibitor MLN8237;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: immunohistochemistry staining method;   Other: pharmacological study
14 Recruiting A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Solid Tumors
Condition: Advanced Malignancies
Intervention: Drug: MLN8237
15 Recruiting A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Patients With Advanced Malignancies
Condition: Advanced Malignancies
Intervention: Drug: MLN8237
16 Recruiting Study of MLN8237 in Patients With Advanced Hematological Malignancies
Conditions: B-cell Follicular Lymphoma;   B-cell Marginal Zone Lymphoma;   Diffuse Large B-cell Lymphoma;   B-cell Mantle Cell Lymphoma;   B-cell Small Lymphocytic Lymphoma (SLL);   B-Cell Chronic Lymphocytic Leukemia (B-CLL);   Multiple Myeloma;   Waldenstrom's Macroglobulinemia
Intervention: Drug: MLN8237
17 Terminated A Study of MLN8054 in Patients With Advanced Solid Tumors
Conditions: Breast Neoplasm;   Colon Neoplasm;   Pancreatic Neoplasm;   Bladder Neoplasm
Intervention: Drug: MLN8054
18 Recruiting Study of MLN8237 in Adults With Aggressive Non-Hodgkin's Lymphoma
Conditions: Diffuse Large B-cell Lymphoma;   Mantle Cell Lymphoma;   Burkitt's Lymphoma;   Precursor B-lymphoblastic Leukemia/Lymphoma;   T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma;   Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component
Intervention: Drug: MLN8237
19 Recruiting A Phase 2 Trial of MLN8237 in Adult Patients With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
Conditions: Acute Myelogenous Leukemia;   High-Grade Myelodysplastic Syndrome
Intervention: Drug: MLN8237
20 Recruiting MLN8237 for Treatment of Patients With Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Condition: Ovarian Carcinoma
Intervention: Drug: MLN8237

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services